Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.13
NYSE:CRL's Cash to Debt is ranked lower than
90% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. NYSE:CRL: 0.13 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:CRL' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.31 Max: N/A
Current: 0.13
Equity to Asset 0.30
NYSE:CRL's Equity to Asset is ranked lower than
83% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. NYSE:CRL: 0.30 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:CRL' s Equity to Asset Range Over the Past 10 Years
Min: -0.28  Med: 0.5 Max: 0.72
Current: 0.3
-0.28
0.72
Interest Coverage 10.45
NYSE:CRL's Interest Coverage is ranked lower than
71% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. NYSE:CRL: 10.45 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:CRL' s Interest Coverage Range Over the Past 10 Years
Min: 4.09  Med: 8.76 Max: 14.87
Current: 10.45
4.09
14.87
F-Score: 6
Z-Score: 2.20
M-Score: -2.68
WACC vs ROIC
6.80%
9.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.56
NYSE:CRL's Operating margin (%) is ranked higher than
82% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. NYSE:CRL: 14.56 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:CRL' s Operating margin (%) Range Over the Past 10 Years
Min: -33.48  Med: 14.58 Max: 18.46
Current: 14.56
-33.48
18.46
Net-margin (%) 9.49
NYSE:CRL's Net-margin (%) is ranked higher than
78% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.51 vs. NYSE:CRL: 9.49 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:CRL' s Net-margin (%) Range Over the Past 10 Years
Min: -38.84  Med: 9.21 Max: 12.55
Current: 9.49
-38.84
12.55
ROE (%) 18.88
NYSE:CRL's ROE (%) is ranked higher than
88% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. NYSE:CRL: 18.88 )
Ranked among companies with meaningful ROE (%) only.
NYSE:CRL' s ROE (%) Range Over the Past 10 Years
Min: -34.11  Med: 12.75 Max: 21.25
Current: 18.88
-34.11
21.25
ROA (%) 6.52
NYSE:CRL's ROA (%) is ranked higher than
76% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. NYSE:CRL: 6.52 )
Ranked among companies with meaningful ROA (%) only.
NYSE:CRL' s ROA (%) Range Over the Past 10 Years
Min: -21.02  Med: 5.98 Max: 7.58
Current: 6.52
-21.02
7.58
ROC (Joel Greenblatt) (%) 26.66
NYSE:CRL's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -10.22 vs. NYSE:CRL: 26.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:CRL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -50.32  Med: 19.05 Max: 37.92
Current: 26.66
-50.32
37.92
Revenue Growth (3Y)(%) 7.00
NYSE:CRL's Revenue Growth (3Y)(%) is ranked higher than
61% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. NYSE:CRL: 7.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:CRL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.6  Med: 7 Max: 13.4
Current: 7
-17.6
13.4
EBITDA Growth (3Y)(%) 8.30
NYSE:CRL's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. NYSE:CRL: 8.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:CRL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.2  Med: 8 Max: 25.2
Current: 8.3
-18.2
25.2
EPS Growth (3Y)(%) 14.50
NYSE:CRL's EPS Growth (3Y)(%) is ranked higher than
77% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. NYSE:CRL: 14.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:CRL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.4  Med: 7.2 Max: 43.3
Current: 14.5
-29.4
43.3
» NYSE:CRL's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CRL Guru Trades in Q3 2015

Ray Dalio 19,687 sh (New)
Joel Greenblatt 29,055 sh (New)
Paul Tudor Jones 16,069 sh (+81.49%)
Pioneer Investments 292,807 sh (+19.58%)
David Dreman 61,274 sh (+4.96%)
Westport Asset Management 155,000 sh (unchged)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
John Rogers 1,674,330 sh (-0.32%)
Ken Fisher 482,899 sh (-5.00%)
PRIMECAP Management 1,437,360 sh (-11.40%)
Jim Simons 816,209 sh (-24.61%)
» More
Q4 2015

CRL Guru Trades in Q4 2015

Steven Cohen 129,500 sh (New)
Paul Tudor Jones 20,336 sh (+26.55%)
Ken Fisher 516,495 sh (+6.96%)
Jim Simons 872,509 sh (+6.90%)
John Rogers 1,742,890 sh (+4.09%)
Westport Asset Management 155,000 sh (unchged)
David Dreman Sold Out
Joel Greenblatt Sold Out
Pioneer Investments 292,345 sh (-0.16%)
PRIMECAP Management 1,271,382 sh (-11.55%)
Ray Dalio 2,687 sh (-86.35%)
» More
Q1 2016

CRL Guru Trades in Q1 2016

Robert Olstein 24,286 sh (New)
David Dreman 57,090 sh (New)
Joel Greenblatt 70,227 sh (New)
Paul Tudor Jones 264,559 sh (+1200.94%)
Jim Simons 950,209 sh (+8.91%)
Ken Fisher 529,834 sh (+2.58%)
Pioneer Investments 293,498 sh (+0.39%)
Westport Asset Management 155,000 sh (unchged)
Ray Dalio Sold Out
John Rogers 1,666,955 sh (-4.36%)
PRIMECAP Management 1,213,160 sh (-4.58%)
Steven Cohen 104,600 sh (-19.23%)
» More
Q2 2016

CRL Guru Trades in Q2 2016

Robert Olstein 55,901 sh (+130.18%)
Steven Cohen Sold Out
David Dreman Sold Out
Ken Fisher 516,128 sh (-2.59%)
Westport Asset Management 150,000 sh (-3.23%)
Pioneer Investments 271,726 sh (-7.42%)
John Rogers 1,464,130 sh (-12.17%)
Jim Simons 780,109 sh (-17.90%)
PRIMECAP Management 970,660 sh (-19.99%)
Paul Tudor Jones 162,837 sh (-38.45%)
Joel Greenblatt 11,856 sh (-83.12%)
» More
» Details

Insider Trades

Latest Guru Trades with CRL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:CPHD, NYSE:ALR, NAS:VWR, NAS:PRXL, NAS:BRKR, NAS:ICLR, NAS:PRAH, OTCPK:CZMWY, NYSE:BIO.B, NAS:INCR, NAS:NEOG, NAS:EXAS, OTCPK:BMXMF, NYSE:PKI, NAS:QGEN, NAS:MYGN, NAS:AXDX, NAS:KANG, NAS:ABAX, NAS:ALOG » details
Traded in other countries:RV6.Germany,
Charles River Laboratories International Inc provides research models and services required to enable in vivo drug discovery and development.

Charles River Laboratories International Inc was incorporated in 1994 in Delaware and in 2000, it completed its initial public offering. It is a full service, early-stage contract research organization. The Company's portfolio includes research models and services required to enabling vivo drug discovery and development. Discovery represents the earliest stages of research in the life sciences, directed at the identification, screening and selection of a lead compound for future drug development. Discovery activities typically extend anywhere from 4-6 years in conventional pharmaceutical research and development timelines. Development activities, which follow, and which can take up to 7-10 years, are directed at demonstrating the safety, tolerability and clinical efficacy of the selected drug candidates. During the preclinical stage of the development process, a drug candidate is tested in vitro (typically on a cellular or sub-cellular level in a test tube or multi-well petri plate) and in vivo (in research models) to support planned or on-going human trials. The Company operates in three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). Through its RMS segment, it has been supplying research models to the drug development industry since 1947. It also provides a variety of related services that are designed to assist its clients in supporting the use of research models in drug discovery and development. Its DSA business segment provides services that enable its clients to outsource their drug discovery research, their critical, regulatory-required safety assessment testing and related drug discovery and development activities. Its Manufacturing segment helps to ensure the safe production and release of products manufactured by its clients. The Microbial Solutions (formerly known as Endotoxin and Microbial Detection or EMD) business provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals and consumer products. The Company's customers include biopharmaceutical companies, small and mid-sized pharmaceutical companies and biotechnology companies, and academic and government institutions. The Company competes in the marketplace based on therapeutic and scientific expertise in in vivo biology, quality, reputation, flexibility, responsiveness, pricing, innovation and capabilities. Its DSA segment competes with in-house departments of pharmaceutical and biotechnology companies, universities and teaching hospitals. The Company also competes with universities and teaching hospitals for outsourced services.

Ratios

vs
industry
vs
history
P/E(ttm) 27.87
CRL's P/E(ttm) is ranked higher than
58% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.60 vs. CRL: 27.87 )
Ranked among companies with meaningful P/E(ttm) only.
CRL' s P/E(ttm) Range Over the Past 10 Years
Min: 8.58  Med: 24.46 Max: 95.66
Current: 27.87
8.58
95.66
Forward P/E 16.10
CRL's Forward P/E is ranked higher than
83% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.74 vs. CRL: 16.10 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.69
CRL's PE(NRI) is ranked higher than
60% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.47 vs. CRL: 27.69 )
Ranked among companies with meaningful PE(NRI) only.
CRL' s PE(NRI) Range Over the Past 10 Years
Min: 8.51  Med: 24.09 Max: 77.86
Current: 27.69
8.51
77.86
Price/Owner Earnings (ttm) 17.43
CRL's Price/Owner Earnings (ttm) is ranked higher than
78% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.42 vs. CRL: 17.43 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CRL' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.56  Med: 23.35 Max: 323.25
Current: 17.43
10.56
323.25
P/B 4.69
CRL's P/B is ranked lower than
64% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. CRL: 4.69 )
Ranked among companies with meaningful P/B only.
CRL' s P/B Range Over the Past 10 Years
Min: 0.75  Med: 2.76 Max: 6
Current: 4.69
0.75
6
P/S 2.61
CRL's P/S is ranked higher than
56% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. CRL: 2.61 )
Ranked among companies with meaningful P/S only.
CRL' s P/S Range Over the Past 10 Years
Min: 1.11  Med: 2.29 Max: 3.88
Current: 2.61
1.11
3.88
PFCF 15.79
CRL's PFCF is ranked higher than
74% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.45 vs. CRL: 15.79 )
Ranked among companies with meaningful PFCF only.
CRL' s PFCF Range Over the Past 10 Years
Min: 8.62  Med: 16.9 Max: 765.42
Current: 15.79
8.62
765.42
POCF 12.79
CRL's POCF is ranked higher than
69% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. CRL: 12.79 )
Ranked among companies with meaningful POCF only.
CRL' s POCF Range Over the Past 10 Years
Min: 4.79  Med: 12.49 Max: 20.15
Current: 12.79
4.79
20.15
EV-to-EBIT 22.13
CRL's EV-to-EBIT is ranked higher than
51% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.20 vs. CRL: 22.13 )
Ranked among companies with meaningful EV-to-EBIT only.
CRL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.7  Med: 17.7 Max: 27.8
Current: 22.13
-10.7
27.8
EV-to-EBITDA 15.14
CRL's EV-to-EBITDA is ranked higher than
53% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.73 vs. CRL: 15.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.5  Med: 12 Max: 16.8
Current: 15.14
-16.5
16.8
Shiller P/E 216.27
CRL's Shiller P/E is ranked lower than
100% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 42.43 vs. CRL: 216.27 )
Ranked among companies with meaningful Shiller P/E only.
CRL' s Shiller P/E Range Over the Past 10 Years
Min: 87.68  Med: 211.28 Max: 1940.5
Current: 216.27
87.68
1940.5
Current Ratio 1.70
CRL's Current Ratio is ranked lower than
68% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. CRL: 1.70 )
Ranked among companies with meaningful Current Ratio only.
CRL' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 2.05 Max: 3.49
Current: 1.7
1.21
3.49
Quick Ratio 1.46
CRL's Quick Ratio is ranked lower than
70% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. CRL: 1.46 )
Ranked among companies with meaningful Quick Ratio only.
CRL' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.73 Max: 3.02
Current: 1.46
0.95
3.02
Days Inventory 38.57
CRL's Days Inventory is ranked higher than
70% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.85 vs. CRL: 38.57 )
Ranked among companies with meaningful Days Inventory only.
CRL' s Days Inventory Range Over the Past 10 Years
Min: 38.5  Med: 41.32 Max: 49.49
Current: 38.57
38.5
49.49
Days Sales Outstanding 65.56
CRL's Days Sales Outstanding is ranked lower than
51% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. CRL: 65.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.42  Med: 59.61 Max: 69.89
Current: 65.56
53.42
69.89
Days Payable 26.76
CRL's Days Payable is ranked lower than
82% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.15 vs. CRL: 26.76 )
Ranked among companies with meaningful Days Payable only.
CRL' s Days Payable Range Over the Past 10 Years
Min: 14.93  Med: 15.63 Max: 26.76
Current: 26.76
14.93
26.76

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.10
CRL's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. CRL: 1.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -62.6  Med: 0.5 Max: 10.3
Current: 1.1
-62.6
10.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.50
CRL's Price/Projected FCF is ranked higher than
65% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. CRL: 1.50 )
Ranked among companies with meaningful Price/Projected FCF only.
CRL' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.95  Med: 1.34 Max: 1.76
Current: 1.5
0.95
1.76
Price/Median PS Value 1.15
CRL's Price/Median PS Value is ranked lower than
57% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. CRL: 1.15 )
Ranked among companies with meaningful Price/Median PS Value only.
CRL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.54  Med: 1.15 Max: 1.8
Current: 1.15
0.54
1.8
Price/Peter Lynch Fair Value 4.16
CRL's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 24 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.27 vs. CRL: 4.16 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CRL' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0  Med: 2.42 Max: 4.16
Current: 4.16
0
4.16
Earnings Yield (Greenblatt) (%) 4.50
CRL's Earnings Yield (Greenblatt) (%) is ranked higher than
78% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. CRL: 4.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.6  Med: 5.5 Max: 14.1
Current: 4.5
3.6
14.1
Forward Rate of Return (Yacktman) (%) 9.46
CRL's Forward Rate of Return (Yacktman) (%) is ranked higher than
53% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.43 vs. CRL: 9.46 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CRL' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 2.8  Med: 5.6 Max: 22.8
Current: 9.46
2.8
22.8

More Statistics

Revenue (TTM) (Mil) $1,492
EPS (TTM) $ 2.96
Beta0.84
Short Percentage of Float3.46%
52-Week Range $59.99 - 89.18
Shares Outstanding (Mil)47.29

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1,665 1,827 1,958 2,165
EPS ($) 4.32 5.09 5.50 6.35
EPS w/o NRI ($) 4.32 5.09 5.50 6.35
EPS Growth Rate
(3Y to 5Y Estimate)
12.67%
Dividends Per Share ($)
» More Articles for NYSE:CRL

Headlines

Articles On GuruFocus.com
Bob Olstein's Olstein Strategic Opportunities Fund 2nd Quarter Commentary Sep 01 2016 
Olstein Strategic Opportunities Fund 1st Quarter Letter to Shareholders Jun 07 2016 
Olstein All Cap Value Fund First Quarter Commentary Jun 01 2016 
Weekly Highlight of CEO Sells Oct 13 2014 
John Rogers Comments on Charles River Laboratories Intl Inc Jul 22 2014 
John Rogers' Ariel Fund Second Quarter 2014 Commentary Jul 22 2014 
Robert Olstein’s Largest New Stock Picks Feb 12 2013 
Weekly CFO Sells HIGHLIGHT: TMO, BLOX, VRSK, CRL, INGR, GWRE Jan 13 2013 
Ariel Funds Top Buys: "We think like Halvorsen: CRL is a buy" Jan 11 2012 
Stocks I Can Buy Much Cheaper Than Halvorsen Did Jan 11 2012 

More From Other Websites
Charles River Laboratories and The Tri-Insitutional Therapeutics Discovery Institute Announce... Sep 22 2016
Charles River Laboratories and The Tri-Insitutional Therapeutics Discovery Institute Announce... Sep 22 2016
Jim Cramer's Top Takeaways: Impinj, Charles River Labs Sep 13 2016
Charles River downgraded by UBS Sep 06 2016
Charles River Laboratories to Present at September Investor Conferences Sep 06 2016
Charles River Laboratories to Present at September Investor Conferences Sep 06 2016
Charles River Laboratories International, Inc. breached its 50 day moving average in a Bullish... Aug 31 2016
Moody's Upgrades Two, Affirms Three and Downgrades One Class of MLCFC 2006-2 Aug 18 2016
Will This Clinical Researcher Become Next Breakout Medical Stock? Aug 11 2016
ETF’s with exposure to Charles River Laboratories International, Inc. : August 10, 2016 Aug 10 2016
CHARLES RIVER LABORATORIES INTERNATIONAL INC Financials Aug 10 2016
Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish... Aug 09 2016
Charles River Laboratories Announces Partnership with the Milner Therapeutics Institute and... Aug 08 2016
Charles River Laboratories Announces Partnership with the Milner Therapeutics Institute and... Aug 08 2016
Charles River Laboratories Announces Partnership with the Milner Therapeutics Institute and... Aug 08 2016
Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q2, 2016 By the Numbers :... Aug 08 2016
Edited Transcript of CRL earnings conference call or presentation 3-Aug-16 12:30pm GMT Aug 03 2016
Charles River Laboratories International Inc Earnings Call scheduled for 8:30 am ET today Aug 03 2016
CHARLES RIVER LABORATORIES INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial... Aug 03 2016
Charles River beats Street 2Q forecasts Aug 03 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)